P/E ratio for Bausch Health (BHC)
P/E ratio as of April 2024 (TTM): -3.28
According to Bausch Health 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.27792. At the end of 2022 the company had a P/E ratio of -10.1.
P/E ratio history for Bausch Health from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -10.1 | -2.64% |
| 2021 | -10.4 | -21.2% |
| 2020 | -13.2 | 123.59% |
| 2019 | -5.90 | 277.72% |
| 2018 | -1.56 | -151.61% |
| 2017 | 3.02 | -244.13% |
| 2016 | -2.10 | -98.41% |
| 2015 | -132 | -350.91% |
| 2014 | 52.6 | -216.52% |
| 2013 | -45.2 | -72.05% |
| 2012 | -162 | -279.91% |
| 2011 | 89.8 | -475.44% |
| 2010 | -23.9 | -290.16% |
| 2009 | 12.6 | 66.36% |
| 2008 | 7.56 | -31.48% |
| 2007 | 11.0 | -31.18% |
| 2006 | 16.0 | 4.03% |
| 2005 | 15.4 | -6.78% |
| 2004 | 16.5 | -119.23% |
| 2003 | -86.0 | -295.29% |
| 2002 | 44.0 | -50.7% |
| 2001 | 89.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.67 | 42.37% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -69.64% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.